Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04988295
Title A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Janssen Research & Development, LLC
Indications

lung non-squamous non-small cell carcinoma

Therapies

Amivantamab-vmjw + Carboplatin + Pemetrexed Disodium

Carboplatin + Pemetrexed Disodium

Amivantamab-vmjw + Carboplatin + Lazertinib + Pemetrexed Disodium

Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL


No variant requirements are available.